The aim of this core is to provide state of the art translational research support services for the novel cellular and immune-based therapies described in the projects in this proposal. Specifically, Core C personnel will perform the large scale production of the NK cell, Treg and Tprog products for the clinical trials in a GMP facility. The Core will also be responsible for the comprehensive immune monitoring of patient and product samples to assess the success of the novel experimental therapies described in Project 1 (T regulatory cells, PI: JE Wagner) and Project 3 (NK cells, PI: JS Miller). Core personnel work closely with the research staff from Core A (Administration) and with the biostatistics and data management staff (Core B: Biostatistics) to facilitate collection and tracking of clinical research samples and provide investigators with complete and accurate immune monitoring data which can be integrated with clinical outcome data.
The Specific Aims of Core C are: 1. To perform large-scale production of NK, Treg and Tprog cells products in a GMP facility 2. To monitor the quality of clinical GMP products 3. To perform comprehensive immune monitoring of patient samples 4. To assist with integration of research and clinical outcome data
Core C supports sample collection, GMP cell product processing and immune monitoring for this program. Immune monitoring is critical for the interpretation of the clinical trials and to help trouble-shoot problems. The Core's shared resources are critical to the scientific integrity between projects and this Program.
|Turcotte, Lucie M; Yingst, Ashley; Verneris, Michael R (2016) Metabolic Syndrome after Hematopoietic Cell Transplantation: At the Intersection of Treatment Toxicity and Immune Dysfunction. Biol Blood Marrow Transplant 22:1159-66|
|Eckfeldt, Craig E; Randall, Nicole; Shanley, Ryan M et al. (2016) Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD. Haematologica 101:e348-51|
|Sarhan, Dhifaf; Cichocki, Frank; Zhang, Bin et al. (2016) Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Cancer Res 76:5696-5706|
|Pritchett, Joshua C; Green, Jaime S; Thomm, Angela M et al. (2016) CD4+ T Cells Coexpressing CD134 (OX40) Harbor Significantly Increased Levels of Human Herpesvirus 6B DNA Following Umbilical Cord Blood Transplantation. J Infect Dis 214:1911-1915|
|Trottier, B J; Sachs, Z; DeFor, T E et al. (2016) Novel disease burden assessment predicts allogeneic transplantation outcomes in myelodysplastic syndrome. Bone Marrow Transplant 51:199-204|
|Brinkman, C Colin; Iwami, Daiki; Hritzo, Molly K et al. (2016) Treg engage lymphotoxin beta receptor for afferent lymphatic transendothelial migration. Nat Commun 7:12021|
|Brunstein, Claudio G; Miller, Jeffrey S; McKenna, David H et al. (2016) Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 127:1044-51|
|Nakamura, Ryotaro; La Rosa, Corinna; Longmate, Jeffrey et al. (2016) Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol 3:e87-98|
|Omer, Aazim K; Weisdorf, Daniel J; Lazaryan, Aleksandr et al. (2016) Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 22:879-83|
|Knorr, David A; Wang, Hongbo; Aurora, Mukta et al. (2016) Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 22:825-33|
Showing the most recent 10 out of 303 publications